Home » Blog » DRESS Syndrome

DRESS Syndrome

By Amigos IAS

Why is it in the news?

  • The Indian Pharmacopoeia Commission (IPC) issues a drug safety alert regarding the painkiller Meftal. Concerns raised about potential adverse reactions, particularly about the risk of DRESS syndrome.

About DRESS Syndrome

  • DRESS stands for Drug Rash with Eosinophilia and Systemic Symptoms.
  • It is an idiosyncratic reaction to certain drugs like abacavir, allopurinol, and lamotrigine.
Idiosyncratic drug reaction: Unpredictable reactions occurring in a small percentage of patients receiving the drug.
  • Delayed onset of symptoms; Includes fever, skin rash, lymphadenopathy (swelling of lymph nodes), eosinophilia (increase in a type of white blood cells), and various systemic manifestations.
  • Characterized by severe symptoms, with an estimated mortality rate of 10 percent.

 

About Meftal

  • Meftal is an over-the-counter medication used for pain and inflammation management.
  • Contains mefenamic acid, a member of the nonsteroidal anti-inflammatory drugs (NSAIDs) class.
  • Prescribed for various conditions such as rheumatoid arthritis, menstrual pain, dental pain, inflammation, and fever.

 

NSAIDs Class

·       Belongs to the class of nonsteroidal anti-inflammatory drugs.

·       Other commonly used NSAIDs include ibuprofen, naproxen, and aspirin.

 

About Indian Pharmacopoeia Commission (IPC)

  • A body operating independently within the Ministry of Health and Family Welfare.
  • Established to set and update drug standards in India.
  • Basic function involves regular updates of drug standards, aligning with prevalent diseases.
  • Publishes official documents (IP) to enhance the quality of medicines through new additions and updates to existing monographs.
  • Contributes to rational use of generic medicines by publishing the National Formulary of India.
  • Provides IP Reference Substances (IPRS) as fingerprints for identification and purity testing of articles under the Indian Pharmacopoeia.

Benefits of International recognition of the Indian pharmacopeia Standards

Boost Export Opportunities:

  • International recognition of Indian Pharmacopeia Standards eliminates double regulation, duplication in testing, and post-importation checks.
  • Boosts export potential for Indian pharmaceutical products.
  • Provides Indian drug exporters with a competitive edge in global markets.

Affordable Access to Quality Products:

  • Enhances affordability as quality pharmaceuticals from India become more accessible in the global market.

Facilitates Generic Medicine Development:

  • International recognition opens avenues for manufacturers in importing countries to engage in the development of generic medicines.
  • Encourages collaboration and contribution to global healthcare solutions.

Signup for newsletter

Receive notifications straight into your inbox

Leave a comment

Item added to cart.
0 items - 0.00

Discover more from AMIGOS IAS

Subscribe now to keep reading and get access to the full archive.

Continue reading